HEPA News and Press, Hepion Pharmaceuticals Inc. From 01/31/20

Novartis Revenue Jumps but Net Income Falls for Q4 Novartis ( NVS ) posted mixed numbers for its fourth quarter. The company announced strong revenue growth but showed negative impact of higher taxes. Its core operating income for the quarter stood at $3.46 billion, up 11 percent while i...

Gainers: Lee Enterprises (NYSE: LEE )  +85% . More news on: Lee Enterprises, Incorporated, Roadrunner Transportation Systems, Inc., Hepion Pharmaceuticals, Inc., Stocks on the move, , Read more ...

Lee Enterprises (NYSE: LEE ) +55%  to acquire BH Media Group’s publications and  The Buffalo News  for $140M. More news on: Lee Enterprises, Incorporated, Hepion Pharmaceuticals, Inc., Genprex, Inc., Stocks on the move, , Read more ...

Penny Stocks To Watch After News If there’s one thing that can trigger a rally in penny stocks , it’s news. Whether it comes from a major industry leader or the company itself, penny stock news can become a big factor in breakouts or break downs. In fact, many times you’...

Hepion Pharmaceuticals (NASDAQ: HEPA ) has jumped 46% after hours after it posted positive lab data for its drug candidate for treating liver disease nonalcoholic steatohepatitis (NASH). More news on: Hepion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read mo...

EDISON, NJ / ACCESSWIRE / January 28, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) ("Hepion" or the "Company"), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today ann...

EDISON, NJ / ACCESSWIRE / January 8, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that it will present a...

Cellect Biotechnology (NASDAQ: APOP ) +141%  on new patents . More news on: Cellect Biotechnology Ltd., Apellis Pharmaceuticals, Inc., Advaxis, Inc., Stocks on the move, Read more ...

Nano cap Hepion Pharmaceuticals (NASDAQ: HEPA ) is up  15%  premarket on modest volume on the heels of a just-published paper supporting the rationale of cyclophilin inhibition for the potential treatment of nonalcoholic steatohepatitis (NASH). More news on: Hepion Pharmaceutic...

EDISON, NJ / ACCESSWIRE / January 6, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that the peer-reviewed...